Servier’s muscular dystrophy drug sevasemten missed endpoints in a pivotal phase 3 trial for Becker muscular dystrophy, according to the company’s statement. The setback follows Servier’s $1.55 billion acquisition of the asset in June, plus up to about $1 billion in potential milestones. The failure in the GRAND CANYON study reverses earlier signals from smaller randomized work that had raised hopes for a treatment in a rare disease without approved therapies. Servier said it is conducting a comprehensive analysis of the GRAND CANYON dataset along with relevant prior clinical data. The news is likely to tighten scrutiny on how broadly prior phase results translate into definitive efficacy in rare neuromuscular indications.